Cargando…
Silver nanoparticles selectively treat triple‐negative breast cancer cells without affecting non‐malignant breast epithelial cells in vitro and in vivo
Silver nanoparticles (AgNPs) show promise for treatment of aggressive cancers including triple‐negative breast cancer (TNBC) in preclinical cancer models. For clinical development of AgNP‐based therapeutics, it will be necessary to clearly define the specific physicochemical features of the nanopart...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6996381/ https://www.ncbi.nlm.nih.gov/pubmed/32123812 http://dx.doi.org/10.1096/fba.2019-00021 |
_version_ | 1783493512973516800 |
---|---|
author | Swanner, Jessica Fahrenholtz, Cale D. Tenvooren, Iliana Bernish, Brian W. Sears, James J. Hooker, Allison Furdui, Cristina M. Alli, Elizabeth Li, Wencheng Donati, George L. Cook, Katherine L. Vidi, Pierre‐Alexandre Singh, Ravi |
author_facet | Swanner, Jessica Fahrenholtz, Cale D. Tenvooren, Iliana Bernish, Brian W. Sears, James J. Hooker, Allison Furdui, Cristina M. Alli, Elizabeth Li, Wencheng Donati, George L. Cook, Katherine L. Vidi, Pierre‐Alexandre Singh, Ravi |
author_sort | Swanner, Jessica |
collection | PubMed |
description | Silver nanoparticles (AgNPs) show promise for treatment of aggressive cancers including triple‐negative breast cancer (TNBC) in preclinical cancer models. For clinical development of AgNP‐based therapeutics, it will be necessary to clearly define the specific physicochemical features of the nanoparticles that will be used, and to tie these properties to biological outcomes. To fill this knowledge gap, we performed thorough structure/function, mechanistic, safety, and efficacy studies to assess the potential for AgNPs to treat TNBC. We establish that AgNPs, regardless of size, shape, or stabilizing agent, are highly cytotoxic to TNBC cells at doses that are not cytotoxic to non‐malignant breast epithelial cells. In contrast, TNBC cells and non‐malignant breast epithelial cells are similarly sensitive to exposure to silver cation (Ag(+)), indicating that the nanoparticle formulation is essential for the TNBC‐specific cytotoxicity. Mechanistically, AgNPs are internalized by both TNBC and non‐malignant breast cells, but are rapidly degraded only in TNBC cells. Exposure to AgNPs depletes cellular antioxidants and causes endoplasmic reticulum stress in TNBC cells without causing similar damage in non‐malignant breast epithelial cells. AgNPs also cause extensive DNA damage in 3D TNBC tumor nodules in vitro, but do not disrupt the normal architecture of breast acini in 3D cell culture, nor cause DNA damage or induce apoptosis in these structures. Lastly, we show that systemically administered AgNPs are effective at non‐toxic doses for reducing the growth of TNBC tumor xenografts in mice. This work provides a rationale for development of AgNPs as a safe and specific TNBC treatment. |
format | Online Article Text |
id | pubmed-6996381 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-69963812020-03-02 Silver nanoparticles selectively treat triple‐negative breast cancer cells without affecting non‐malignant breast epithelial cells in vitro and in vivo Swanner, Jessica Fahrenholtz, Cale D. Tenvooren, Iliana Bernish, Brian W. Sears, James J. Hooker, Allison Furdui, Cristina M. Alli, Elizabeth Li, Wencheng Donati, George L. Cook, Katherine L. Vidi, Pierre‐Alexandre Singh, Ravi FASEB Bioadv Research Articles Silver nanoparticles (AgNPs) show promise for treatment of aggressive cancers including triple‐negative breast cancer (TNBC) in preclinical cancer models. For clinical development of AgNP‐based therapeutics, it will be necessary to clearly define the specific physicochemical features of the nanoparticles that will be used, and to tie these properties to biological outcomes. To fill this knowledge gap, we performed thorough structure/function, mechanistic, safety, and efficacy studies to assess the potential for AgNPs to treat TNBC. We establish that AgNPs, regardless of size, shape, or stabilizing agent, are highly cytotoxic to TNBC cells at doses that are not cytotoxic to non‐malignant breast epithelial cells. In contrast, TNBC cells and non‐malignant breast epithelial cells are similarly sensitive to exposure to silver cation (Ag(+)), indicating that the nanoparticle formulation is essential for the TNBC‐specific cytotoxicity. Mechanistically, AgNPs are internalized by both TNBC and non‐malignant breast cells, but are rapidly degraded only in TNBC cells. Exposure to AgNPs depletes cellular antioxidants and causes endoplasmic reticulum stress in TNBC cells without causing similar damage in non‐malignant breast epithelial cells. AgNPs also cause extensive DNA damage in 3D TNBC tumor nodules in vitro, but do not disrupt the normal architecture of breast acini in 3D cell culture, nor cause DNA damage or induce apoptosis in these structures. Lastly, we show that systemically administered AgNPs are effective at non‐toxic doses for reducing the growth of TNBC tumor xenografts in mice. This work provides a rationale for development of AgNPs as a safe and specific TNBC treatment. John Wiley and Sons Inc. 2019-09-30 /pmc/articles/PMC6996381/ /pubmed/32123812 http://dx.doi.org/10.1096/fba.2019-00021 Text en © 2019 The Authors. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Articles Swanner, Jessica Fahrenholtz, Cale D. Tenvooren, Iliana Bernish, Brian W. Sears, James J. Hooker, Allison Furdui, Cristina M. Alli, Elizabeth Li, Wencheng Donati, George L. Cook, Katherine L. Vidi, Pierre‐Alexandre Singh, Ravi Silver nanoparticles selectively treat triple‐negative breast cancer cells without affecting non‐malignant breast epithelial cells in vitro and in vivo |
title | Silver nanoparticles selectively treat triple‐negative breast cancer cells without affecting non‐malignant breast epithelial cells in vitro and in vivo |
title_full | Silver nanoparticles selectively treat triple‐negative breast cancer cells without affecting non‐malignant breast epithelial cells in vitro and in vivo |
title_fullStr | Silver nanoparticles selectively treat triple‐negative breast cancer cells without affecting non‐malignant breast epithelial cells in vitro and in vivo |
title_full_unstemmed | Silver nanoparticles selectively treat triple‐negative breast cancer cells without affecting non‐malignant breast epithelial cells in vitro and in vivo |
title_short | Silver nanoparticles selectively treat triple‐negative breast cancer cells without affecting non‐malignant breast epithelial cells in vitro and in vivo |
title_sort | silver nanoparticles selectively treat triple‐negative breast cancer cells without affecting non‐malignant breast epithelial cells in vitro and in vivo |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6996381/ https://www.ncbi.nlm.nih.gov/pubmed/32123812 http://dx.doi.org/10.1096/fba.2019-00021 |
work_keys_str_mv | AT swannerjessica silvernanoparticlesselectivelytreattriplenegativebreastcancercellswithoutaffectingnonmalignantbreastepithelialcellsinvitroandinvivo AT fahrenholtzcaled silvernanoparticlesselectivelytreattriplenegativebreastcancercellswithoutaffectingnonmalignantbreastepithelialcellsinvitroandinvivo AT tenvooreniliana silvernanoparticlesselectivelytreattriplenegativebreastcancercellswithoutaffectingnonmalignantbreastepithelialcellsinvitroandinvivo AT bernishbrianw silvernanoparticlesselectivelytreattriplenegativebreastcancercellswithoutaffectingnonmalignantbreastepithelialcellsinvitroandinvivo AT searsjamesj silvernanoparticlesselectivelytreattriplenegativebreastcancercellswithoutaffectingnonmalignantbreastepithelialcellsinvitroandinvivo AT hookerallison silvernanoparticlesselectivelytreattriplenegativebreastcancercellswithoutaffectingnonmalignantbreastepithelialcellsinvitroandinvivo AT furduicristinam silvernanoparticlesselectivelytreattriplenegativebreastcancercellswithoutaffectingnonmalignantbreastepithelialcellsinvitroandinvivo AT allielizabeth silvernanoparticlesselectivelytreattriplenegativebreastcancercellswithoutaffectingnonmalignantbreastepithelialcellsinvitroandinvivo AT liwencheng silvernanoparticlesselectivelytreattriplenegativebreastcancercellswithoutaffectingnonmalignantbreastepithelialcellsinvitroandinvivo AT donatigeorgel silvernanoparticlesselectivelytreattriplenegativebreastcancercellswithoutaffectingnonmalignantbreastepithelialcellsinvitroandinvivo AT cookkatherinel silvernanoparticlesselectivelytreattriplenegativebreastcancercellswithoutaffectingnonmalignantbreastepithelialcellsinvitroandinvivo AT vidipierrealexandre silvernanoparticlesselectivelytreattriplenegativebreastcancercellswithoutaffectingnonmalignantbreastepithelialcellsinvitroandinvivo AT singhravi silvernanoparticlesselectivelytreattriplenegativebreastcancercellswithoutaffectingnonmalignantbreastepithelialcellsinvitroandinvivo |